Cidara Therapeutics Inc Stock
Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cidara Therapeutics Inc Stock
Our community identified positive and negative aspects for Cidara Therapeutics Inc stock for the coming years. 1 users see the criterium "Revenue growth" as a plus for the Cidara Therapeutics Inc stock. On the other hand our users think that "Company culture" could be a problem in the future.
Pros and Cons of Cidara Therapeutics Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
B****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cidara Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cidara Therapeutics Inc | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | 1.180% | 8.974% | 17.241% | -40.351% | -8.602% | -10.053% | -81.048% |
| Vaxart Inc. | 21.640% | -0.639% | -15.408% | -49.275% | -58.457% | -74.601% | -95.556% |
| Achieve Life Sciences Inc. | 1.550% | -1.382% | 1.552% | 1.290% | 10.098% | 62.459% | -37.200% |
Comments
News
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
On November 14, 2025, Bain Capital Life Sciences Investors, LLC disclosed a purchase of 520,310 shares of Cidara Therapeutics (NASDAQ:CDTX), increasing its position value by approximately $167.48
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.
Just prior to last week's takeover news, Cidara Therapeutics (NASDAQ: CDTX) was already one of the year's top-performing stocks. Trading in the mid-$20s at the start of 2025, by mid-November, this
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover
California-based TCG Crossover Management fully exited its position in Cidara Therapeutics (NASDAQ:CDTX) during the third quarter, reducing its holdings by 1 million shares in a move valued at